Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers and Outcomes in Rectal Cancer Neoadjuvant Therapy
NCT04418895Phase 2Withdrawn
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Aug 2021
- Primary completion
- May 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, fluorouracil, capecitabine in rectal adenocarcinoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Planned start Aug 2021; status: withdrawn.
02
Drugs
oxaliplatinfluorouracilcapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT04418895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418895.